Ubs Group Ag Molecular Partners Ag Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MOLN
# of Institutions
6Shares Held
849KCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA443KShares$2.58 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY400KShares$2.33 Million0.08% of portfolio
-
Morgan Stanley New York, NY500Shares$2,9150.0% of portfolio
-
Rhumbline Advisers Boston, MA269Shares$1,5680.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About MOLECULAR PARTNERS AG
- Ticker MOLN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,514,000
- Market Cap $190M
- Description
- Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...